(Q36047244)

11 August 2017

1 reference

title

The evolution of domain arrangements in proteins and interaction networks (English)

1 reference

11 August 2017

0 references

1

1 reference

11 August 2017

4

Teichmann SA

1 reference

11 August 2017

Beaussart F

2

1 reference

PubMed ID

15719170

11 August 2017

Kummerfeld SK

series ordinal

3

1 reference

PubMed ID

15719170

11 August 2017

Weiner J 3rd

series ordinal

5

1 reference

11 August 2017

1 February 2005

1 reference

Cellular and Molecular Life Sciences

11 August 2017

1 reference

11 August 2017

62

1 reference

11 August 2017

435-445

1 reference

11 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-004-4416-1

11 August 2017

0 references

cites work

Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know

1 reference

12 December 2020

Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia

1 reference

12 December 2020

The emerging role of HDL in glucose metabolism

1 reference

12 December 2020

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

1 reference

12 December 2020

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

12 December 2020

[PCSK9 as new target in hyperlipidemia treatment].

1 reference

12 December 2020

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

12 December 2020

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome

1 reference

12 December 2020

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

1 reference

12 December 2020

Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study

1 reference

12 December 2020

High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice

1 reference

12 December 2020

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

1 reference

12 December 2020

Excess Mortality among Persons with Type 2 Diabetes

1 reference

12 December 2020

Molecular basis of PCSK9 function

1 reference

12 December 2020

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

12 December 2020

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

12 December 2020

Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids

1 reference

12 December 2020

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

1 reference

12 December 2020

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

12 December 2020

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

12 December 2020

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

12 December 2020

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

12 December 2020

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus

1 reference

12 December 2020

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

1 reference

12 December 2020

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

1 reference

12 December 2020

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

1 reference

12 December 2020

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis

1 reference

12 December 2020

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

12 December 2020

Diabetic dyslipidemia

1 reference

12 December 2020

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

12 December 2020

Whole-Body MR Imaging Including Angiography: Predicting Recurrent Events in Diabetics.

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

1 reference

12 December 2020

Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus

1 reference

12 December 2020

Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes.

1 reference

12 December 2020

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

12 December 2020

10.1007/S00018-004-4416-1

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15719170